An ad-hoc group of infectious disease doctors and health researchers on Tuesday held a public meeting to review recent ...

With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

"New study shows RSV vaccine highly effective in older U.S. veterans during 2023-2024 respiratory illness season. Only 24% of eligible adults received vaccine, ...

For adults over age 60, who are at higher risk for serious complications from RSV because immune systems weaken with age, the U.S. Food and Drug Administration (FDA) approved two vaccines.

Respiratory syncytial virus vaccine uptake was low among older veterans, with disparities observed across demographic and social risk factors.

During the 2023–2024 RSV season, 15,521 nirsevimab doses were administered to infants and children aged 0 to 19 months in NYC, as reported to the Citywide Immunization Registry.

The research, published Friday in JAMA Network Open, analyzed data from 7,047 RSV-tested lower respiratory tract disease cases at Kaiser Permanente Southern California between November 2023 and ...

She said every year the PICU is full of infants critically ill with RSV infection. However, the new immunization – approved in July 2023 – is over 90% effective at preventing hospitalization.

About 177,000 older adults were hospitalized last year from RSV and the state of Oklahoma saw a two-year peak in RSV cases in December of 2023. These trends show the importance of protecting ...

Havers FP, Whitaker M, Melgar M, et al. Burden of respiratory syncytial virus–associated hospitalizations in US adults, October 2016 to September 2023. JAMA Netw Open. 2024;7 (11):e2444756. doi ...